4McConnell YD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. NEnglJMed 1998; 338(9): 557-563.
5Levy MA, Brandt M, Sheedy KM, et al. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J Steroid Biochem Mol Biol 1994; 48(2-3): 197-206.
7Roehrbom CG, Schwinn DA. Alphal-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Uro12004; 171(3): 1029- 1035.
8McConnell JD, Roehrbom CG, Bautista OM,et al. The long-term effect of doxazosin, fmasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEnglJMed 2003; 349(25): 2387-2398.
9Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Uro12006; 175: 217-220, discussion 220-221.
10McConne11 JD, Bruskewitz R, Walsh P, et al. The effect of finas- teride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Tern1 Ett~cacy and Safety Study Group. N Engl J Med, 1998, 338(9) :557-563.
